A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network

Journal of Molecular Modeling

Volumn 17, Issue 10, 2011, Pages 2693-2705

  Rücker, Pia ^a   Horn, Anselm H C ^a   Meiselbach, Heike ^a   Sticht, Heinrich ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

HIV; HTLV; Molecular dynamics simulation; Protein structure; Protein ligand interactions

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; MOLECULAR SCAFFOLD;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; COMPARATIVE STUDY; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; LIGAND BINDING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN FOLDING;

AMINO ACID SEQUENCE; ASPARTIC ACID ENDOPEPTIDASES; CONSERVED SEQUENCE; HIV PROTEASE; HIV-1; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SUBSTRATE SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 80255138809     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-011-0971-1     Document Type: Article

References (63)

1. BJ Poiesz FW Ruscetti AF Gazdar PA Bunn JD Minna RC Gallo 1980 Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma Proc Natl Acad Sci USA 77 7415 7419 10.1073/pnas.77.12.7415 1:CAS:528:DyaL3MXhtlOnt74%3D (Pubitemid 11131140)
2. M Yoshida M Seiki K Yamaguchi K Takatsuki 1984 Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease Proc Natl Acad Sci USA 81 2534 2537 10.1073/pnas.81.8.2534 1:STN:280:DyaL2c7psVSntg%3D%3D
3. A Gessain F Barin JC Vernant O Gout L Maurs A Calender G de The 1985 Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis Lancet 2 8452 407 410 10.1016/S0140-6736(85)92734-5 1:STN:280:DyaL2M3psVyitA%3D%3D (Pubitemid 15231248)
4. L LaGrenade B Hanchard V Fletcher B Cranston W Blattner 1990 Infective dermatitis of Jamaican children: a marker for HTLV-I infection Lancet 336 8727 1345 1347 10.1016/0140-6736(90)92896-P 1:STN:280:DyaK3M%2FktFCitA%3D%3D
5. M Mochizuki T Watanabe K Yamaguchi K Takatsuki K Yoshimura M Shirao S Nakashima S Mori S Araki N Miyata 1992 HTLV-I uveitis: a distinct clinical entity caused by HTLV-I Jpn J Cancer Res 83 236 239 10.1111/j.1349-7006.1992. tb00092.x 1:STN:280:DyaK383lvFaqtw%3D%3D
6. OS Morgan P Rodgers-Johnson C Mora G Char 1989 HTLV-1 and polymyositis in Jamaica Lancet 2 8673 1184 1187 10.1016/S0140-6736(89)91793-5 1:STN:280:DyaK3c%2Fkt1yksw%3D%3D
7. K Nishioka I Maruyama K Sato I Kitajima Y Nakajima M Osame 1989 Chronic inflammatory arthropathy associated with HTLV-I Lancet 1 8635 441 441 10.1016/S0140-6736(89)90038-X 1:STN:280:DyaL1M7kt1ygsQ%3D%3D
8. G de The R Bomford 1993 An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 9 381 386 10.1089/aid.1993.9.381
9. A Gessain 1996 Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection J Neurovirol 2 299 306 10.3109/13550289609146894 1:STN:280:DyaK2s%2FmvFSiug%3D%3D (Pubitemid 26372455)
10. D Zucker-Franklin BA Pancake 1998 Human T-cell lymphotropic virus type 1 tax among American blood donors Clin Diagn Lab Immunol 5 831 835 1:STN:280:DyaK1M%2FhvFOruw%3D%3D (Pubitemid 28519261)
11. F Barré-Sinoussi JC Chermann F Rey MT Nugeyre S Chamaret J Gruest C Dauguet C Axler-Blin F Vézinet-Brun C Rouzioux W Rozenbaum L Montagnier 1983 Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 220 868 871 10.1126/science.6189183
12. RC Gallo SZ Salahuddin M Popovic GM Shearer M Kaplan BF Haynes TJ Palker R Redfield J Oleske S Bea 1984 Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS Science 224 500 503 10.1126/science.6200936 1:STN:280:DyaL2c7nt1aisA%3D%3D (Pubitemid 14134741)
13. NE Kohl EA Emmi WA Schleif LJ Davies JC Heimbach RAF Dixon 1988 Active human immunodeciency virus protease is required for viral infectivity Proc Natl Acad Sci 85 686 690
14. K Ishitsuka K Tamura 2008 Treatment of adult T-cell leukemia/lymphoma: past, present, and future Eur J Haematol 80 185 196 10.1111/j.1600-0609.2007. 01016.x 1:CAS:528:DC%2BD1cXktVKisr8%3D (Pubitemid 351253463)
15. JM Louis S Oroszlan J Tozser 1999 Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase J Biol Chem 274 6660 6666 10.1074/jbc.274.10.6660 1:CAS:528:DyaK1MXhs1Cgs74%3D (Pubitemid 29111086)
16. M Li GS Laco M Jaskolski J Rozycki J Alexandratos A Wlodawer A Gustchina 2005 Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design Proc Natl Acad Sci USA 102 18332 18337 10.1073/pnas.0509335102 1:CAS:528:DC%2BD28Xpt1Cj (Pubitemid 43011226)
17. HM Berman J Westbrook Z Feng G Gilliland TN Bhat H Weissig IN Shindyalov PE Bourne 2000 The protein data bank Nucleic Acids Res 28 235 242 10.1093/nar/28.1.235 1:CAS:528:DC%2BD3cXhvVKjt7w%3D (Pubitemid 30047768)
18. Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, Clawson L, Selk L, Kent SB, Wlodawer A (1989) Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science 246:1149-1152 (Pubitemid 20012771)
19. Wartha F, Horn AHC, Meiselbach H, Sticht H (2005) Molecular dynamics simulations of HIV-1 protease suggest different mechanisms contributing to drug resistance. J Chem Theory Comput 1:315-324
20. P Dirauf H Meiselbach H Sticht 2010 Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease J Mol Model 16 1577 1583 10.1007/s00894-010-0677-9 1:CAS:528:DC%2BC3cXht1Kjt7rO
21. H Meiselbach AH Horn T Harrer H Sticht 2007 Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations J Mol Model 13 297 304 10.1007/s00894-006-0121-3 1:CAS:528:DC%2BD2sXisFantLw%3D (Pubitemid 46189159)
22. a values for protein-ligand complexes. Proteins 73:765-783 (Pubitemid 352788657)
23. R Smith IM Brereton RY Chai SB Kent 1996 Ionization states of the catalytic residues in HIV-1 protease Nat Struct Biol 3 946 950 10.1038/nsb1196-946 1:CAS:528:DC%2BD38Xms1Clsbk%3D (Pubitemid 26398328)
24. DA Case T Cheatham T Darden H Gohlke R Luo KM Merz A Onufriev C Simmerling B Wang R Woods 2005 The Amber biomolecular simulation programs J Comput Chem 26 1668 1688 10.1002/jcc.20290 1:CAS:528:DC%2BD2MXht1SlsbbM (Pubitemid 43076180)
25. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, KMerz M, Pearlman DA, Crowley M, Walker RC, Zhang W, Wang B, Hayik S, Roitberg A, Seabra G, Wong KF, Paesani F, Wu X, Brozell S, Tsui V, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Beroza P, Mathews DH, Schafmeister C, Ross WS, Kollman PA (2006) AMBER 9. University of California, San Francisco
26. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE 3rd, DeBolt S, Ferguson D, Seibel G, Kollman P (1995) AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comp Phys Commun 91:1-41
27. TE Cheatham 3rd P Cieplak PA Kollman 1999 A modified version of the Cornell, et al.. force field with improved sugar pucker phases and helical repeat J Biomol Struct Dyn 16 845 862 1:CAS:528:DyaK1MXitF2jsb8%3D (Pubitemid 29157655)
28. WD Cornell P Cieplak CI Bayly IR Gould KMJ Merz DM Ferguson DC Spellmeyer T Fox JW Caldwell PA Kollman 1995 A second generation force field for the simulaton of proteins, nucleic acids and organic molecules J Am Chem Soc 117 5179 5197 10.1021/ja00124a002 1:CAS:528:DyaK2MXlsFertrc%3D
29. WL Jorgensen J Chandrasekhar JD Madura RW Impey ML Klein 1983 Comparison of simple potential functions for simulating liquid water J Chem Phys 79 926 935 10.1063/1.445869 1:CAS:528:DyaL3sXksF2htL4%3D
30. J Wang RM Wolf JW Caldwell PA Kollman DA Case 2004 Development and testing of a general amber force field J Comput Chem 25 1157 1174 10.1002/jcc.20035 1:CAS:528:DC%2BD2cXksFakurc%3D
31. TA Darden DM York LG Pedersen 1993 Particle mesh Ewald. An N.log(N) method for Ewald sums in large systems J Chem Phys 98 10089 10092 10.1063/1.464397 1:CAS:528:DyaK3sXks1Ohsr0%3D
32. JP Ryckaert G Ciccotti HJC Berendsen 1977 Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J Comput Phys 23 327 341 10.1016/0021-9991(77)90098-5 1:CAS:528:DyaE2sXktVGhsL4%3D
33. Tripos (1991-2008) Sybyl 7.3. Tripos, St. Louis
34. Accelrys (2005) DS ViewerPro Suite 6.0. Accelrys, San Diego
35. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8:127-134
36. BG Luukkonen W Tan EM Fenyo S Schwartz 1995 Analysis of cross reactivity of retrovirus proteases using a vaccinia virus-T7 RNA polymerase-based expression system J Gen Virol 76 2169 2180 10.1099/0022-1317-76-9-2169
37. P Bagossi J Kadas G Miklossy P Boross IT Weber J Tozser 2004 Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases J Virol Methods 119 87 93 10.1016/j.jviromet.2004.03.001 1:CAS:528:DC%2BD2cXkt1Smurg%3D (Pubitemid 38670399)
38. Kadas J, Weber IT, Bagossi P, Miklossy G, Boross P, Oroszlan S, Tozser J (2004) Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell leukemia virus type 1 protease. J Biol Chem 279:27148-27157 (Pubitemid 38812551)
39. J Tozser G Zahuczky P Bagossi JM Louis TD Copeland S Oroszlan RW Harrison IT Weber 2000 Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases Eur J Biochem 267 6287 6295 10.1046/j.1432-1327.2000.01714.x 1:CAS:528:DC%2BD3cXnsVygtro%3D
40. J Tozser A Gustchina IT Weber I Blaha EM Wondrak S Oroszlan 1991 Studies on the role of the S4 substrate binding site of HIV proteinases FEBS Lett 279 356 360 10.1016/0014-5793(91)80186-7 1:CAS:528:DyaK3MXkt1Gjsrs%3D
41. A Gustchina IT Weber 1990 Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap FEBS Lett 269 269 272 10.1016/0014-5793(90)81171-J 1:CAS:528:DyaK3cXlvVOjurw%3D (Pubitemid 20245369)
42. ES Furfine E D'Souza KJ Ingold JJ Leban T Spector DJ Porter 1992 Two-step binding mechanism for HIV protease inhibitors Biochemistry 31 7886 7891 10.1021/bi00149a020 1:CAS:528:DyaK38XltVeltro%3D
43. EJ Rodriguez C Debouck IC Deckman H Abu-Soud FM Raushel TD Meek 1993 Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry Biochemistry 32 3557 3563 10.1021/bi00065a006 1:CAS:528:DyaK3sXisFSmt7o%3D (Pubitemid 23126929)
44. V Hornak A Okur RC Rizzo C Simmerling 2006 HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations Proc Natl Acad Sci USA 103 915 920 10.1073/pnas.0508452103 1:CAS:528:DC%2BD28XhsVKgt7w%3D (Pubitemid 43212196)
45. AL Perryman JH Lin JA McCammon 2004 HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs Protein Sci 13 1108 1123 10.1110/ps.03468904 1:CAS:528:DC%2BD2cXivFaktbY%3D (Pubitemid 38429231)
46. G Toth A Borics 2006 Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases Biochemistry 45 6606 6614 10.1021/bi060188k 1:CAS:528: DC%2BD28XktVSmu7k%3D (Pubitemid 43825361)
47. S Spinelli QZ Liu PM Alzari PH Hirel RJ Poljak 1991 The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU Biochimie 73 1391 1396 10.1016/0300-9084(91)90169-2 1:CAS:528:DyaK38Xht1eqs7s%3D
48. DI Freedberg R Ishima J Jacob YX Wang I Kustanovich JM Louis DA Torchia 2002 Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations Protein Sci 11 221 232 10.1110/ps.33202 1:CAS:528: DC%2BD38XosFylsw%3D%3D (Pubitemid 34075785)
49. R Ishima DI Freedberg YX Wang JM Louis DA Torchia 1999 Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function Structure 7 1047 1055 10.1016/S0969-2126(99) 80172-5 1:CAS:528:DyaK1MXmtlartL8%3D (Pubitemid 29436502)
50. L Galiano F Ding AM Veloro ME Blackburn C Simmerling GE Fanucci 2009 Drug pressure selected mutations in HIV-1 protease alter flap conformations J Am Chem Soc 131 430 431 10.1021/ja807531v 1:CAS:528:DC%2BD1cXhsFantbrE
51. H Heaslet R Rosenfeld M Giffin YC Lin K Tam BE Torbett JH Elder DE McRee CD Stout 2007 Conformational flexibility in the flap domains of ligand-free HIV protease Acta Crystallogr D Biol Crystallogr 63 866 875 10.1107/ S0907444907029125 (Pubitemid 47094569)
52. JL Kear ME Blackburn AM Veloro BM Dunn GE Fanucci 2009 Subtype polymorphisms among HIV-1 protease variants confer altered flap conformations and flexibility J Am Chem Soc 131 14650 14651 10.1021/ja907088a 1:CAS:528:DC%2BD1MXhtF2lurrP
53. SA Seibold RI Cukier 2007 A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions Proteins 69 551 565 10.1002/prot.21535 1:CAS:528:DC%2BD2sXht1aju7%2FK (Pubitemid 47623871)
54. HIVDB Team (1998-2008) Stanford HIV Database. http://hivdb.stanford.edu/
55. AL Perryman Q Zhang HH Soutter R Rosenfeld DE McRee AJ Olson JE Elder C David Stout 2010 Fragment-based screen against HIV protease Chem Biol Drug Des 75 257 268 10.1111/j.1747-0285.2009.00943.x 1:CAS:528:DC%2BC3cXit1Ois7c%3D
56. S Alcaro A Artese F Ceccherini-Silberstein F Ortuso CF Perno T Sing V Svicher 2009 Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance J Chem Inf Model 49 1751 1761 10.1021/ci900012k 1:CAS:528:DC%2BD1MXnsVeit7g%3D
57. A Kontijevskis P Prusis R Petrovska S Yahorava F Mutulis I Mutule J Komorowski JE Wikberg 2007 A look inside HIV resistance through retroviral protease interaction maps PLoS Comput Biol 3 424 435 10.1371/journal.pcbi. 0030048 1:CAS:528:DC%2BD2sXjvVSis7k%3D (Pubitemid 46535735)
58. B Mahalingam JM Louis CC Reed JM Adomat J Krouse YF Wang RW Harrison IT Weber 1999 Structural and kinetic analysis of drug resistant mutants of HIV-1 protease Eur J Biochem 263 238 245 10.1046/j.1432-1327.1999.00514.x 1:CAS:528:DyaK1MXkslKrtrk%3D (Pubitemid 29313860)
59. IT Weber RW Harrison 1999 Molecular mechanics analysis of drug-resistant mutants of HIV protease Protein Eng 12 469 474 10.1093/protein/12.6.469 1:CAS:528:DyaK1MXkslGhsb0%3D (Pubitemid 29322444)
60. M Kozisek J Bray P Rezacova K Saskova J Brynda J Pokorna F Mammano L Rulisek J Konvalinka 2007 Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants J Mol Biol 374 1005 1016 10.1016/j.jmb.2007.09.083 1:CAS:528:DC%2BD2sXht1ykurjK (Pubitemid 350052096)
61. H Ode S Neya M Hata W Sugiura T Hoshino 2006 Computational simulations of HIV-1 proteases-multi-drug resistance due to nonactive site mutation L90M J Am Chem Soc 128 7887 7895 10.1021/ja060682b 1:CAS:528:DC%2BD28XkvVehtbg%3D (Pubitemid 43945729)
62. W Sherman B Tidor 2008 Novel method for probing the specificity binding profile of ligands: applications to HIV protease Chem Biol Drug Des 71 387 407 10.1111/j.1747-0285.2008.00659.x 1:CAS:528:DC%2BD1cXlsVSrt78%3D (Pubitemid 351519509)
63. JE Foulkes-Murzycki WR Scott CA Schiffer 2007 Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease Structure 15 225 233 10.1016/j.str.2007.01.006 1:CAS:528: DC%2BD2sXhs1Smsrg%3D (Pubitemid 46209819)